Tomas Blomquist – CEO, Biotage, Sweden

16.10.2019
Biotage, a Swedish company that specializes in separation technology, from analysis to industrial scale, and high-quality solutions for organic and analytical chemistry, has been a story of success since its creation in 1997. Upcoming CEO, Tomas Blomquist, provides insights into the company’s goal of becoming the market leader in separation science and outlines his ambitious strategy after he takes over on November 6, 2019.  
Biotage is a separation science company and is based in the world capital of separation science, Uppsala
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In
Tags:
Sweden, Biotage, Strategy

Related Interviews

Martina Stenerdal – General Manager, PPD Scandinavia

As a worldwide research powerhouse, Sweden is benefiting from the presence of multinational clinical research organizations like PPD. Martina Stenerdal, general manager for PPD in Scandinavia, discusses the company’s 25-year…

Jan Hellqvist – General Manager, KLIFO Sweden

With almost three decades of experience in the Swedish life science industry, Jan Hellqvist, general manager of KLIFO in Sweden, explains why the country has seen the number of clinical…

Anders Millerhovf – CEO, CTC Clinical Trial Consultants, Sweden

In a fast-changing Nordic CRO industry, CTC Clinical Trial Consultants has opted to differentiate with a unique one-stop-shop approach. CEO Anders Millerhovf reveals how the relatively young company has managed…

Related Articles

Nordics / Danish-Swedish Clinical Trial Collaboration: Better Together?

Denmark boasts plenty of strong fundamentals as a clinical trials hub, but is perhaps constrained by a population of just 5.8 million and a correspondingly small patient pool. However, international…

Europe / Sustainability & Pharma Procurement: Are You ‘Green’ Enough? 

In the wake of the 2021 United Nations Climate Change Conference (COP26), sustainability is once more a hot-button issue across all industries, including pharma. Here, Marco Rauland, vice president global…

Sweden / A Global Testbed for AMR Incentive Models

Anders Blanck, CEO of Lif, the trade association for the research-based Swedish pharmaceutical industry, writes about the challenges the world faces from antimicrobial resistance (AMR). Sweden has for decades been…

Latest Report

Switzerland Pharma Report June 2021

Related Content

Sweden
Biotage
Strategy